Clinical Trial

Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

Study acronym: LETERCOR
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."
Trial Details
NCT Number NCT06057194
Lead Sponsor Maimónides Biomedical Research Institute of Córdoba
Collaborators: MERCK SHARP & DOHME DE ESPAÑA S.A.
Conditions Infections, Cytomegalovirus
Enrollment 90 participants
Start Date 2023-10
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2023-09-28